Down 13% in 1 Day, Is Moderna Stock in Trouble?
Moderna 's (NASDAQ: MRNA) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...
Down More Than 50%, Is It Time to Buy Moderna Stock as the Biotech Charts a New Post-COVID Path?
With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...
After Moderna's Shocking News, Is the Stock a Buy or a Sell?
Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...
Moderna: Cutting Costs At Just The Worst Time
Moderna shares have dropped by over -41.67% since I last covered them over the summer. See why I continue to rate MRNA stock ...
Moderna Stock Keeps Falling. An Analyst's Downgrade Isn't Helping
Moderna shares are down for the second day in a row after the company said it would slash its research and development costs.
Moderna forecasts lower sales next year, shares near four-year low
Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...
Moderna was most shorted S&P 500 healthcare stock in August for second consecutive month
Short interest for healthcare stocks in S&P 500 increased during August end vs. last month, with Moderna being most shorted ...
Behind the Scenes of Moderna's Latest Options Trends
Present Market Standing of Moderna Trading volume stands at 5,013,059, with MRNA's price down by -2.52%, positioned at $68.1. RSI indicators show the stock to be may be approaching oversold. Earnings ...
Moderna’s ‘Off-the-Shelf’ Cancer Vaccine Shows Promise in Early Human Trial Data
The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...
Moderna lays out plan to slice research and development spending
Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending ...
Moderna: Still Bullish View
Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...